
Ocugen Inc (NASDAQ:OCGN) shares are trading lower by 22.8% at $2.54 after the company announced the FDA declined to issue an EUA for COVAXIN for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 2 to 18 years of age.
Ocugen says the company intends to continue working with the FDA to evaluate the regulatory pathway for the pediatric use of COVAXIN.